Previous Close | 30.68 |
Open | 31.00 |
Bid | 22.40 x 100 |
Ask | 38.98 x 100 |
Day's Range | 30.30 - 31.16 |
52 Week Range | 15.81 - 37.04 |
Volume | |
Avg. Volume | 2,126,357 |
Market Cap | 3.828B |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.28 |
Earnings Date | Feb 20, 2025 - Feb 24, 2025 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 43.00 |
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score.
PALO ALTO, Calif., November 13, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units ("RSUs") representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 50,349 shares of its common stock to three new non-executive employees with a gr